Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing

$PMD
Medical Specialities
Health Care
Get the next $PMD alert in real time by email

DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report. This report provides an in-depth analysis of drug trends within educational institutions, shedding light on the growing challenges schools face in maintaining a drug-free environment for students and staff.

Following the success of our inaugural Workforce Insights Report earlier this year, we continue our commitment to providing groundbreaking insights based on data from hair testing. For the Education Insights Report, Psychemedics analyzed thousands of hair samples collected from students and staff in educational settings across the United States. The data offer valuable perspectives on drug use trends over the past five years, supporting schools in their efforts to combat substance abuse.

The 2024 Education Insights Report reveals key findings, including:

  • Rising Drug Positivity Rates: The overall positivity rate for drug tests in the education sector has increased by 25%, rising from 3.9% to 4.9% over the last five years.
  • Top Drugs Detected: Marijuana, nicotine, amphetamines, and cocaine were among the most commonly detected substances. Marijuana was present in 57.6% of positive tests, with nicotine following at 17.9%.
  • Emerging Delta-8 Trend: National data reveals that 11% of 12th-grade students used Delta-8 THC in the past year, a new and less understood substance gaining popularity among teens.
  • Challenges of Legalization: As marijuana legalization expands across states, schools are facing increased challenges in preventing underage access. The report highlights the importance of health and wellness-focused drug testing programs to create safer learning environments.

"Our Education Insights Report marks a pivotal moment for Psychemedics as we expand our focus to address the growing concerns of substance abuse within schools and universities," said Brian Hullinger, Chief Executive Officer at Psychemedics. "By leveraging our innovative hair testing solutions, we aim to provide educational institutions with the tools they need to effectively monitor and address drug use, ensuring the safety and well-being of both students and staff."

The report underscores the growing importance of drug testing within educational settings, as schools across the nation work to maintain safe and healthy environments. With hair testing offering long detection windows and unmatched accuracy, Psychemedics is at the forefront of helping schools manage these critical challenges.

To access the full Education Insights Report and learn more about Psychemedics' hair testing solutions for educational institutions, visit https://www.psychemedics.com/whitepaper/.

For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit https://www.psychemedics.com.

About Psychemedics

Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

Investor Relations:

Phone: 978-206-8220

Email: InvestorRelations@psychemedics.com



Primary Logo

Get the next $PMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PMD

DatePrice TargetRatingAnalyst
More analyst ratings

$PMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • Psychemedics Corporation Announces Reverse and Forward Stock Split

    DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) (the "Company"), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the "Reverse Stock Split") followed immediately by a 5,000-for-1 forward stock split of its common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Stock Split"), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 202

    $PMD
    Medical Specialities
    Health Care
  • Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders

    DALLAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing, reminds its stockholders to vote ahead of the Company's upcoming annual meeting of stockholders scheduled for November 25, 2024. Each stockholder's vote is important. The Company's Board of Directors recommends that stockholders vote "FOR" each proposal at the annual meeting. Instructions for voting your shares are set forth below. The record date for the annual meeting is October 8, 2024. If you have previously voted your shares and do not wish to change your vote, you do not need to take any action. If you have already voted or given your proxy and wish to change your vote,

    $PMD
    Medical Specialities
    Health Care
  • Psychemedics Corporation Reports Third Quarter 2024 Financial Results

    DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024. The Company's revenue for three months ended September 30, 2024, was $5.2 million versus $5.7 million for three months ended September 30, 2023, a decrease of 9%. Net loss was $0.5 million, or $0.09 per share, compared to a net loss of $2.1 million, or $0.36 per share, for the three months ended September 2024 and 2023, respectively. The Company's revenue for nine months ended September 30, 2024, was $15.3 million versus $17.1 million for nine months ended Septem

    $PMD
    Medical Specialities
    Health Care

$PMD
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PMD
SEC Filings

See more

$PMD
Leadership Updates

Live Leadership Updates

See more
  • Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

    ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

    $NBSE
    $PMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
  • Psychemedics Corporation Reports Third Quarter 2023 Financial Results

    ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company's revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year. The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Res

    $PMD
    Medical Specialities
    Health Care
  • Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

    ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. Her appointment marks a significant milestone for Psychemedics Corporation as it continues to expand its presence in the rapidly evolving field of substance abuse testing. "We are

    $PMD
    Medical Specialities
    Health Care

$PMD
Financials

Live finance-specific insights

See more
  • Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

    ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana's legal landscape evolving in 49 states, it's clear that the time for

    $PMD
    Medical Specialities
    Health Care
  • Psychemedics Corporation Reports Second Quarter 2023 Financial Results

    ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company's revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year. In the second quarter, the labor shortage continued to have an adverse impact on our clients' use of hair testing in hirin

    $PMD
    Medical Specialities
    Health Care
  • Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

    ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company's revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last ye

    $PMD
    Medical Specialities
    Health Care

$PMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more